Xinlitai announced that the company and its wholly-owned subsidiary have received an acceptance notice from the State Drug Administration, and the clinical trial application for injectable SAL012, a class 1 new drug developed independently for the treatment of advanced solid tumors, has been accepted. The acceptance number is CXSL2600858. If no negative or questionable opinions have been received within 60 days from the date of acceptance, clinical trials may be carried out in accordance with the submitted plan.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.